These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23709007)

  • 1. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
    Takeshita A
    Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ; Laszlo GS; Estey EH; Walter RB
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
    Brotelle T; Lemal R; Moluçon-Chabrot C; Bay JO; Delaunay J; Guièze R
    Bull Cancer; 2014 Feb; 101(2):211-8. PubMed ID: 24557850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
    Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
    Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
    Lo Coco F; Ammatuna E; Noguera N
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
    Duong HK; Sekeres MA
    Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
    Thol F; Schlenk RF
    Expert Opin Biol Ther; 2014 Aug; 14(8):1185-95. PubMed ID: 24865510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
    O'Hear C; Rubnitz JE
    Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.
    Breccia M; Lo-Coco F
    Expert Opin Biol Ther; 2011 Feb; 11(2):225-34. PubMed ID: 21142804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stasi R; Evangelista ML; Buccisano F; Venditti A; Amadori S
    Cancer Treat Rev; 2008 Feb; 34(1):49-60. PubMed ID: 17942233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.